Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

11/20/24 11:56:39 AM ET

$BDRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BDRX alert in real time by email

SC 13G/A 1 ea0221977-13ga1brio_bio.htm AMENDMENT NO. 1 TO SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

(Amendment No. 1)

UNDER THE SECURITIES EXCHANGE ACT OF 1934*

BIODEXA PHARMACEUTICALS PLC

(Name of Issuer)

AMERICAN DEPOSITORY SHARES**

(Title of Class of Securities)

59564R708***

(CUSIP Number)

November 14, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

***

The CUSIP number applies to the American Depositary Shares of the Issuer.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 59564R708

1.	Names of Reporting Persons Brio Capital Master Fund Ltd.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Cayman Islands

Number of Shares

Beneficially Owned

By Each Reporting

Person With:

Sole Voting Power

167,681 American Depository Shares^{(1) (2)}

Shared Voting Power

Sole Dispositive Power

167,681 American Depository Shares ^{(1) (2)}

Shared Dispositive Power

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 167,681 American Depository Shares^{(1) (2)}
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒ See footnote (2) below. (See Instructions)
11.	Percent of Class Represented by Amount in Row (9) .9%⁽³⁾
12.	Type of Reporting Person (See Instructions) CO

(1)

Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

(2)

This amount includes American Depository Shares issuable upon exercise of the Warrants.

(3)

Percentage calculation is based on the number of ordinary shares outstanding as of November 14, 2024, as reported on the company’s website.

CUSIP No. 59564R708

1.	Names of Reporting Persons Brio Capital Management LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware, United States

Number of Shares

Beneficially Owned

By Each Reporting

Person With:

Sole Voting Power

167,681 American Depository Shares ⁽⁴⁾⁽⁵⁾

Shared Voting Power

Sole Dispositive Power

167,681 American Depository Shares ⁽⁴⁾⁽⁵⁾

Shared Dispositive Power

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 167,681 American Depository Shares ⁽⁴⁾⁽⁵⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒ See footnote (5) below. (See Instructions)
11.	Percent of Class Represented by Amount in Row (9) .9%⁽⁶⁾
12.	Type of Reporting Person (See Instructions) CO

(4)

(5)

This amount includes American Depository Shares issuable upon exercise of the Warrants.

(6)

Percentage calculation is based on the number of ordinary shares outstanding as of November 14, 2024, as reported on the company’s website.

Item 1(a).	Name of Issuer

	Biodexa Pharmaceuticals PLC (the “Issuer”)

Item 1(b).	Address of the Issuer’s Principal Executive Offices

	1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom.

Item 2(a).	Names of Persons Filing

	This Schedule 13G is filed jointly by:

	Brio Capital Master Fund Ltd.
	Brio Capital Management LLC

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person.

Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

Item 2(b).	Address of the Principal Business Office, or if none, Residence:

	c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401 W. Rockville Center, NY 11570.

Item 2(c).	Citizenship

Brio Capital Master Fund Ltd. – Cayman Islands

Brio Capital Management LLC – United States

Item 2(d).	Title of Class of Securities

	American Depository Shares. Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

Item 2(e).	CUSIP Number

	59564R708

Item 3.	If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

	¨	(a) Broker or Dealer registered under Section 15 of the Exchange Act.

	¨	(b) Bank as defined in Section 3(a)(b) or the Exchange Act.

	¨	(c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.

	¨	(d) Investment company registered under Section 8 of the Investment Company Act.

	¨	(e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).

	¨	(f) An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).

	¨	(g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).

	¨	(h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.

	¨	(i) A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

	¨	(j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).

		Not applicable

Item 4.

Ownership

The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference.

Item 5.	Ownership of Five Percent or Less of a Class

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not Applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not Applicable

Item 8.	Identification and Classification of Members of the Group

	Not Applicable

Item 9.	Notice of Dissolution of Group

	Not Applicable

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: November 20, 2024

Brio Capital Master Fund Ltd.,
a Cayman Islands Exempted Company

By:	Brio Capital Management LLC, its Investment Manager

By:	/s/ Shaye Hirsch
	Name:	Shaye Hirsch
	Title:	Managing Member

Brio Capital Management LLC,
a Delaware limited liability company

By:	/s/ Shaye Hirsch
	Name:	Shaye Hirsch
	Title:	Managing Member

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

(See 18 U.S.C. 1001)

Get the next $BDRX alert in real time by email

Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

Chat with this insight

Recent Analyst Ratings for
$BDRX

$BDRX
SEC Filings

SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

$BDRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.